Acacia Research reported a revenue of $13.5 million, up from $5.8 million in the same quarter last year, which includes $10.9 million from Printronix. The company experienced a GAAP Net Loss of $73.3 million, or ($1.61) per diluted share, compared to a net loss of $164.5 million, or ($2.81) per diluted share, in the first quarter of last year. The company completed $15.0 million of share repurchases and anticipates receiving a $26 million milestone payment from Mycovia Pharmaceuticals.
Total revenues were $13.5 million, compared to $5.8 million in the same quarter last year, including $10.9 million from Printronix.
Recorded $66.9 million in realized gains during the quarter, including $59.5 million from the Life Sciences Portfolio.
Completed $15.0 million of share repurchase under authorization announced in December 2021, repurchasing 3.1 million shares at an average price of $4.80.
GAAP Net Loss of $(73.3) million, or ($1.61) per diluted share, compared to net loss of $(164.5) million, or $(2.81) per diluted share, in the first quarter of last year.
Acacia anticipates attractive acquisition opportunities due to dislocations in the capital markets, leveraging its strong capital position and partnership with Starboard Value, LP.
Visualization of income flow from segment revenue to net income